{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=41", "query": { "intervention": "Control II", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 2668, "total_pages": 267, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=42&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=40&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T09:37:33.279Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02407054", "title": "A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "LY3023414", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 142, "start_date": "2015-04-29", "completion_date": "2020-04-16", "has_results": true, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 36, "location_summary": "Homewood, Alabama • Fayetteville, Arkansas • Marina del Rey, California + 31 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Marina del Rey", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02407054" }, { "nct_id": "NCT01896531", "title": "A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2013-08-14", "completion_date": "2021-01-26", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 3, "location_summary": "Los Angeles, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896531" }, { "nct_id": "NCT05889156", "title": "Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Triglycerides" ], "interventions": [ { "name": "NST-1024", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NorthSea Therapeutics B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 50, "start_date": "2023-06-30", "completion_date": "2025-04-11", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "La Mesa", "state": "California" }, { "city": "North Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05889156" }, { "nct_id": "NCT00336102", "title": "Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Fatigue", "Hypothyroidism" ], "interventions": [ { "name": "physiologic testing", "type": "OTHER" }, { "name": "fatigue assessment and management", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "20 Years to 80 Years · Female only" }, "enrollment_count": 541, "start_date": "2006-04", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2015-07-09", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Loveland", "state": "Colorado" }, { "city": "Leesburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00336102" }, { "nct_id": "NCT00683722", "title": "PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive", "Pulmonary Emphysema", "Chronic Bronchitis" ], "interventions": [ { "name": "Prochymal™", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mesoblast, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 62, "start_date": "2008-03-20", "completion_date": "2010-08-24", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 6, "location_summary": "Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00683722" }, { "nct_id": "NCT01563445", "title": "Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Bleeding Disorder", "Intracerebral Haemorrhage" ], "interventions": [ { "name": "activated recombinant human factor VII", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2001-11", "completion_date": "2003-03", "has_results": false, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01563445" }, { "nct_id": "NCT02261753", "title": "Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cortical Dysplasia" ], "interventions": [ { "name": "Classical ketogenic diet", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University College, London", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "15 Years", "sex": "ALL", "summary": "3 Years to 15 Years" }, "enrollment_count": 3, "start_date": "2014-10", "completion_date": "2017-07-26", "has_results": false, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02261753" }, { "nct_id": "NCT04566601", "title": "A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Personality Disorder" ], "interventions": [ { "name": "BI 1358894", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 390, "start_date": "2020-11-13", "completion_date": "2023-01-25", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 16, "location_summary": "Anaheim, California • Temecula, California • Upland, California + 13 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566601" }, { "nct_id": "NCT01498328", "title": "A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Small Cell Glioblastoma", "Giant Cell Glioblastoma", "Gliosarcoma", "Glioblastoma With Oligodendroglial Component", "Recurrent Glioblastoma", "Relapsed Glioblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Rindopepimut (CDX-110) with GM-CSF", "type": "DRUG" }, { "name": "KLH", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2011-12", "completion_date": "2016-05-17", "has_results": false, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498328" }, { "nct_id": "NCT00378131", "title": "Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer Cachexia" ], "interventions": [ { "name": "RC-1291", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Therapeutics (U.S.), Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2006-09", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2013-09-02", "last_synced_at": "2026-10-28T09:37:33.279Z", "location_count": 17, "location_summary": "Glendale, Arizona • Encinitas, California • Santa Monica, California + 13 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Lafayette", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00378131" } ] }